You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, January 2014
|
| DOI | 10.1186/2051-1426-2-2 |
| Pubmed ID | |
| Authors |
Shailender Bhatia, Brendan Curti, Marc S Ernstoff, Michael Gordon, Elisabeth I Heath, Wilson H Miller, Igor Puzanov, David I Quinn, Thomas W Flaig, Peter VanVeldhuizen, Kelly Byrnes-Blake, Jeremy A Freeman, Rachel Bittner, Naomi Hunder, Sonia Souza, John A Thompson |
| Abstract |
Despite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory properties, plus sorafenib, a VEGFR tyrosine kinase inhibitor. |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 17% |
| Student > Master | 7 | 17% |
| Student > Bachelor | 6 | 15% |
| Professor | 3 | 7% |
| Student > Ph. D. Student | 3 | 7% |
| Other | 7 | 17% |
| Unknown | 8 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 20% |
| Immunology and Microbiology | 7 | 17% |
| Biochemistry, Genetics and Molecular Biology | 5 | 12% |
| Agricultural and Biological Sciences | 5 | 12% |
| Engineering | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 10 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2014.
All research outputs
#4,858,208
of 25,461,852 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,259
of 3,436 outputs
Outputs of similar age
#53,907
of 323,253 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#3
of 15 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,436 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,253 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.